Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Clinical Trials

A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile

Not Applicable

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Lansoprazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Metronidazole

First Posted Date: 2023-07-03

Last Posted Date: 2024-12-20

Lead Sponsor: Miguel O'Ryan Gallardo

Target Recruit Count: 500

Registration Number: NCT05926804

Locations: 🇨🇱
Universidad de Chile, Santiago, Chile
🇨🇱
Universidad de Aysén, Coyhaique, Chile
🇨🇱
Universidad de la Frontera, Temuco, Chile

Biofunctionalization of a Volume-stable Collagen Matrix (VCMX) for the Treatment of Single Gingival Recession

Not Applicable

Recruiting

Conditions: Gingival Recession

Interventions: Procedure: CAF
Procedure: i-PRF
Device: VCMX
Drug: Sodium dipyrone
Drug: Chlorhexidine rinse
Drug: Amoxicillin 500mg

First Posted Date: 2023-06-23

Last Posted Date: 2023-06-23

Lead Sponsor: Universidade Estadual Paulista Júlio de Mesquita Filho

Target Recruit Count: 75

Registration Number: NCT05916742

Locations: 🇧🇷
São Paulo State University, São José Dos Campos, São Paulo, Brazil

Use of a Novel Volume-stable Collagen Matrix (VCMX) in the Treatment of Single Gingival Recession Associated With Non-carious Cervical Lesion Partially Restored

Not Applicable

Recruiting

Conditions: Gingival Recession, Localized
Tooth Abrasion

Interventions: Procedure: Restorative procedure
Procedure: Coronally Advanced Flap (CAF).
Drug: Sodium dipyrone
Device: Volume-stable collagen matrix (VCMX)
Drug: Amoxicillin 500mg

First Posted Date: 2023-06-23

Last Posted Date: 2023-06-23

Lead Sponsor: Universidade Estadual Paulista Júlio de Mesquita Filho

Target Recruit Count: 50

Registration Number: NCT05916716

Locations: 🇧🇷
Sao Paulo State University, São José Dos Campos, SP, Brazil

High-dose Dual Therapy with Different Administration Frequencies

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: vonoprazan
Drug: Amoxicillin

First Posted Date: 2023-06-13

Last Posted Date: 2024-12-30

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 327

Registration Number: NCT05901051

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

Phase 3

Not yet recruiting

Conditions: Infections Joint Prosthetic

Interventions: Drug: amoxicillin or moxifloxacin + rifampicin
Drug: amoxicillin or moxifloxacin

First Posted Date: 2023-06-13

Last Posted Date: 2024-03-13

Lead Sponsor: Centre Hospitalier Universitaire de Nice

Target Recruit Count: 235

Registration Number: NCT05902221

Locations: 🇫🇷
CH Annecy Genevois, Annecy, France
🇫🇷
CHU de BORDEAUX, Bordeaux, France
🇫🇷
HCL, Lyon, France

and more 9 locations

Rescue Therapy for Helicobacter Pylori Infection

Phase 4

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Vonoprazan
Drug: Bismuth Potassium Citrate
Drug: Amoxicillin
Drug: Tetracycline
Drug: Rifabutin
Drug: Metronidazole

First Posted Date: 2023-05-25

Last Posted Date: 2024-12-30

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 360

Registration Number: NCT05874544

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳
Shanghai Songjiang District Central Hospital, Shanghai, Shanghai, China
🇨🇳
The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang, China

Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）

Not Applicable

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Tegoprazan
Drug: Amoxicillin
Drug: Esomeprazole

First Posted Date: 2023-05-23

Last Posted Date: 2023-07-11

Lead Sponsor: Yanqing Li

Target Recruit Count: 368

Registration Number: NCT05870683

Locations: 🇨🇳
Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China

Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children

Phase 2

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Esomeprazole
Drug: Lansoprazole
Drug: Amoxicillin
Drug: Clarithromycin

First Posted Date: 2023-05-17

Last Posted Date: 2023-05-17

Lead Sponsor: Finni Kollins

Target Recruit Count: 51

Registration Number: NCT05861687

Locations: 🇮🇩
Universitas Sumatera Utara General Hospital, Medan, North Sumatera, Indonesia
🇮🇩
Haji Adam Malik General Hospital, Medan, North Sumatera, Indonesia